CHRS

Coherus Oncology Inc

1.45

Jul 02 • 04:00PM ET +0.01 (0.69%)

Healthcare Biotechnology USA Micro NASD

Peers: CCCC REPL ZNTL ALEC CLLS ELDN IMRX LENZ GLSI RZLT

| Held by: VTI IWM VXF IWN SCHA VTWO IWO IWC PRFZ SCHB

Scroll to Statements

Index	RUT
Market Cap	223.66M
Enterprise Value	110.98M
Income	-151.66M
Sales	46.88M
Book/sh	0.51
Cash/sh	1.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	147
IPO	Nov 06, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	4.77
P/B	2.84
P/C	1.34
P/FCF	-
EV/EBITDA	-
EV/Sales	2.37
Quick Ratio	1.52
Current Ratio	1.56
Debt/Eq	0.69
LT Debt/Eq	0.67
Option/Short	Yes / Yes

EPS (ttm)	-1.25
EPS next Y	-0.64
EPS next Q	-0.24
EPS this Y	34.94%
EPS next Y	37.14%
EPS next 5Y	32.26%
EPS past 3/5Y	27.14% -
Sales past 3/5Y	-41.54% -38.41%
EPS Y/Y TTM	-9.93%
Sales Y/Y TTM	-76.26%
EPS Q/Q	43.03%
Sales Q/Q	61.99%
Earnings	May 11 AMC
EPS/Sales Surpr.	-2.54% -13.42%

Insider Own	24.85%
Insider Trans	0.00%
Inst Own	35.60%
Inst Trans	6.26%
ROA	-54.20%
ROE	-860.65%
ROIC	-115.69%
Gross Margin	60.04%
Oper. Margin	-362.07%
Profit Margin	-323.49%
SMA20	0.57%
SMA50	-8.43%
SMA200	-10.09%
Trades

Shs Outstand	154.22M
Shs Float	115.92M
Short Float	22.12%
Short Ratio	22.90
Short Interest	25.64M
52W High	2.62 -44.57%
52W Low	0.73 97.82%
Volatility	5.64% 6.05%
ATR (14)	0.09
RSI (14)	46.33
Beta	0.98
Rel Volume	0.76
Avg Volume	1.12M
Volume	851,333

Perf Week	-2.03%
Perf Month	-4.61%
Perf Quarter	-16.67%
Perf Half Y	2.84%
Perf YTD	2.11%
Perf Year	82.37%
Perf 3Y	-66.04%
Perf 5Y	-89.44%
Perf 10Y	-91.39%
Recom	1.43
Target Price	7.80
Prev Close	1.44
Price	1.45
Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
May-11-26	Initiated	Guggenheim	Buy	$12
Jan-23-26	Initiated	Oppenheimer	Outperform	$10
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15

Show Previous Ratings

Jun-23-26 02:00PM	Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-12-26 08:30AM	Coherus Oncology, Inc. Q1 2026 Earnings Call Summary (Moby) -12.31%
03:07AM	Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ... (GuruFocus.com)
May-11-26 04:23PM	Coherus Oncology: Q1 Earnings Snapshot (Associated Press) +11.43%
04:05PM	Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:30AM	Loading…
May-04-26 09:30AM	Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
Mar-09-26 11:01PM	Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +6.04%
05:35PM	Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:38PM	Coherus Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-08-26 05:27AM	Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts (MarketBeat)
Mar-02-26 09:30AM	Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 (GlobeNewswire)
Feb-26-26 12:15PM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-24-26 09:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates (Zacks)
Feb-23-26 07:25PM	Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:30AM	Loading…
09:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-17-26 04:11PM	Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Feb-12-26 09:18PM	Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -19.90%
05:20PM	Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates (Zacks)
04:05PM	Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire) +10.09%
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-14-26 06:14AM	Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains? (Zacks) -5.88%
Jan-06-26 09:30AM	Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.56%
Jan-05-26 09:30AM	Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) (GlobeNewswire) +5.11%
Dec-08-25 08:30AM	Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma (GlobeNewswire) +6.67%
Nov-07-25 09:00AM	Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody (GlobeNewswire) -10.07%
12:09AM	Coherus Oncology Inc (CHRS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 08:15PM	Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:10PM	Coherus Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:14PM	Loading…
04:14PM	Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
01:54PM	Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer (GlobeNewswire)
Oct-30-25 05:35PM	Illumina (ILMN) Beats Q3 Earnings and Revenue Estimates (Zacks)
08:30AM	Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-23-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-03-25 09:05AM	Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-03-25 08:30AM	Coherus Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.88%
Aug-08-25 08:18AM	Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences (Pharmaceutical Business Review) -7.13%
03:40AM	Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:30PM	Coherus Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:41PM	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
10:29AM	Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA® (PR Newswire)
Jul-31-25 04:45PM	Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -6.64%
Jun-25-25 09:55AM	Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? (Zacks) -6.08%
Jun-06-25 04:29PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
May-30-25 08:00AM	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire)
May-27-25 08:30AM	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-13-25 02:22PM	Q1 2025 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -19.11%
03:10AM	Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.30%
04:27PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:45AM	What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings (GuruFocus.com)
May-05-25 04:01PM	Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -7.27% -8.83%
May-01-25 05:04PM	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:10AM	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire)
Apr-17-25 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

ChairmanMr. Dennis M. Lanfear

Chief Financial OfficerMr. Bryan J. McMichael

Vice President of Investor Relations & AdvocacyMs. Carrie Graham

Chief Legal OfficerMr. Andy Rittenberg

Chief Human Resources OfficerMs. Rebecca Sunshine

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

CHRS

Coherus Oncology Inc

Upgrade your Finviz experience